Clinical Trial

A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Study acronym: FIL_MAB
Recruiting
View on ClinicalTrials.gov →
Summary
This is a prospective, observational cohort study to evaluate the clinical impact of novel Monoclonal AntiBodies (MAB) in B-cell Non-Hodgkin Lymphoma (NHL) in Italian clinical practice.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-08-18; most recent amendment 2025-12-22.
Status change: Not Yet Recruiting → Recruiting 2024-06-27
Trial Details
NCT Number NCT06008691
Lead Sponsor Fondazione Italiana Linfomi - ETS
Collaborators: Roche Pharma AG
Conditions Non-Hodgkin Lymphoma, B-cell
Enrollment 1,500 participants
Start Date 2023-12-27
Primary Completion 2038-10 (estimated)
Study Completion 2038-10 (estimated)
Updated on ClinicalTrials.gov 2025-12-29